The Society of Cancer Management
  • Home
    • An After Life
    • News Archive
  • About
    • Terms & Conditions
    • Privacy Policy
    • Copyright Notice
  • Contact

. . . supporting research that improves cancer survival.

 
Please contact us if you would like to contribute a news item. We are keen to publish more articles from UK-based research and findings that relate to microbial infections during therapy.

Pazopanib improves progression-free survival without impairing health-related quality of life

6/7/2015

0 Comments

 
In patients with soft tissue sarcoma, whose disease had progressed during or after prior chemotherapy, pazopanib improved progression-free survival but did not change health-related quality of life. This observed improvement in progression-free survival without impairment of health-related quality of life was considered a meaningful result.

There has not been a lot of research that has looked into the quality of life of patients with advanced soft tissue sarcoma. The results of this European Organisation for Research and Treatment of Cancer (EORTC) health related quality of life study show that the application of pazopanib for soft tissue sarcoma is quite complicated. This study included an array of outcome assessments including not only efficacy and toxicity but also cost effectiveness and patient-reported outcomes, and it has provided much needed data.

Dr. Andrew Bottomley, Head of the EORTC Quality of Life Department and co-author of this study says "This is one of the few randomized clinical trials with quality of life studies undertaken in metastatic soft-tissue sarcoma in such a robust manner. It's so important to better understand what treatment options we can offer to these patients, and we hope our results shed more light onto a field that in the past had remained much in the dark."

Prof. Winette van der Graaf of Radboud University Medical Center Nijmegen, The Netherlands and coordinator of EORTC trial 62072 points out, "The EORTC health related quality of life study was comprehensive, and although multiple indicators might complicate interpretation of the results, they also provide a more thorough assessment of the impact of pazopanib therapy on the patients and on the impact on the health care system. In the end, this is what is needed to translate clinical trial results to the bedside."

Corneel Coens, EORTC Biostatistician and lead author of this study explains, "One of the intentions of this study was to investigate if, by delaying tumor progression, pazopanib would improve the quality of life of these sarcoma patients. An ambitious project as this is a relative rare and mixed patient population with little prior data about quality of life. This study informs us about the treatment balance between improving outcome at the cost of side effects."

This study was conducted by the EORTC Soft-Tissue Sarcoma Group and the EORTC Quality of Life Department and supported by a grant from GlaxoSmithKline. Health-related quality of life was assessed using the 30-item core EORTC Quality-of-Life Questionnaire (EORTC QLQ-C30) at baseline and at weeks 4, 8, and 12 in patients who received treatment on protocol.

Coens et al. Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy—a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Global Network Study (EORTC 62072). Cancer. 2015; doi: 10.1002/cncr.29426 [Abstract]
0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    Cancer Therapy & Palliative Care News

    This feed features recent developments in cancer therapy and palliative care. Views in these articles do not necessarily represent those of the Cancer Management Society.

    Archives

    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013

    Categories

    All
    General
    Presentation
    Research
    Review

    RSS Feed

Home

About

Contact Us

Terms & Conditions

Privacy Policy

Copyright Notice

RSS Feed

Proudly powered by Weebly
© The Society of Cancer Management 2017